A Study to Evaluate the Safety and Immunogenicity of RSVpreF Coadministered With Herpes Zoster Vaccine in Adults

计划入组 526 人 · 首次发布于 2025 年 3 月 24 日

Phase I Study for SynGEM, an Intranasal Respiratory Syncytial Virus (RSV) Prefusion F Subunit Candidate Vaccine

计划入组 48 人 · 首次发布于 2016 年 11 月 8 日

A Study to Learn About the Safety and Immune Activity of RSVpreF in Children 2 to <18 Years of Age

计划入组 128 人 · 首次发布于 2023 年 6 月 12 日

Bivalent Respiratory Syncytial Virus prefusion F vaccine(Pfizer)(Abrysvo)

MV-012-968

STR-V003

Vaxart

United States

Hualan Biological Vaccine Inc.

China

AB&B BIO-TECH-B

Pfizer Receives CDSCO Approval for Phase III RSV Vaccine Trial in India with Conditional Requirements

RSV Vaccine Safety Profile Monitored Across Age Groups and Populations

RSV Vaccine Development Surges with New Approvals and Diverse Strategies